New study lends fresh insights into how pelvic floor muscle (PFM) training works by reducing contractions of the detrusor muscle of the overactive bladder, reports the American Journal of Physical Medicine & Rehabilitation, the official journal of the Association of Academic Physiatrists. The journal is published by Wolters Kluwer.
Pelvic floor muscle contractions can reduce the severity of contractions of the detrusor muscle of the bladder in patients with OAB, including those with and without multiple sclerosis, according to the new research by Adelia Lucio, PhD, of HUMAP - UFMS, Campo Grande, Brazil.
Overactive bladder is a very common condition, causing urinary urgency and incontinence. Symptoms of OAB can be improved by performing PFM training, sometimes called Kegel exercises. Dr. Lucio and colleagues designed a laboratory study to explore the mechanisms by which pelvic floor muscle contractions work to improve OAB symptoms.
The researchers performed urodynamic studies in two groups of women. Eighteen patients had OAB symptoms related to multiple sclerosis (MS), a chronic central nervous system disease. About 80 percent of patients with MS experience "neurogenic" (nerve damage-related) bladder symptoms sometime during the course of their disease.
Another 17 patients had "idiopathic" OAB, which means that no specific cause of their urinary symptoms was identified. Symptoms were similar between groups, based on a standard OAB questionnaire.
In the experimental procedure, the women were instructed to perform a 15-second PFM contraction during a period of detrusor muscle overactivity. The study focused on overactivity of the detrusor muscle: the muscle in the bladder wall that contracts to help push urine out of the bladder. The results confirmed that contracting the pelvic floor muscles led to reduction in the pressure produced by detrusor overactivity. Although the decrease in detrusor muscle pressure with PFM contraction was significant in both groups, the effect was larger in patients with idiopathic OAB. For this group, the median decrease in detrusor overactivity was 69 percent, compared to 34 percent in the patients with MS.
Pelvic floor muscle contraction completely eliminated detrusor overactivity in eight of the 17 women with idiopathic OAB, compared to three of 18 women with MS. The difference likely reflects the more severe disability and greater detrusor overactivity in MS patients with OAB symptoms. Although PFM contractions were still effective in MS patients with neurogenic bladder symptoms, the link may be weaker due to neurological damage throughout the brain and spinal cord.
Pelvic floor muscle contractions activate the frontal cortex of the brain, which is responsible for the "voluntary urinary inhibition reflex" - thus improving conscious control of bladder function. The authors believe their study adds to the evidence that PFM contractions are a potentially useful clinical tool for patients suffering from OAB.
Polyuria is the excessive production and passage of urine, having multiple causes and several treatment modalities.
You may want to avoid popping the overactive bladder drug as a recent study has linked it with an increased risk of depression.
Kegel exercises include exercises that make the muscles in the pelvic region stronger and benefit individuals with bowel control problems and urinary leakage.
A recent study showed that physically active men are at lower risk of nocturia, waking up at night to urinate.
Abnormalities of bowel storage, poor urine stream and pelvic pain are signs of pelvic floor disorders that can be corrected with exercises and kegels in women.
Pelvic Organ Prolapse (POP) is the dropping (herniation) of the pelvic organs due to loss of normal support of the muscles of the pelvic floor.


text:
Todd Gurley Eligible to Play November 15
via AJC
The NCAA issued a statement on suspended Georgia running back Todd Gurley.
Georgia's star running back must sit a total of four games, or 30 percent of the season, for accepting more than $3,000 in cash from multiple individuals for autographed memorabilia and other items over two years.
Gurley, who acknowledged violating NCAA rules, must repay a portion of the money received to a charity of his choice and complete 40 hours of community service as additional conditions for his reinstatement.
Gurley will be eligible to play on Nov. 15.
5 Reasons to Start a Business in Atlanta
What's Coming to Six Flags in 2015?
AT&T Shares High-Tech Halloween Ideas for Atlantans

redpajama_set_name: RedPajamaCommonCrawl


Early investigations at Fort Ancient were conducted in the form of mapping expeditions in the early 1800s and expanded towards the end of the century to surface collecting and full-scale excavations by William King Moorehead, a local man from Xenia, Ohio. Moorehead, along with others, was convinced that the impressive bluff-top embankment walls were created to defend against invaders. Later research showed, however, that Fort Ancient represents an embankment of ceremonial space rather than a fortress. Archaeological investigations have been nearly continuous at Fort Ancient since Moorehead, but the techniques used and the information gained have drastically changed how the site is viewed.
In 2005, Dr. Jarrod Burks performed remote sensing, a method for detecting what is below the ground without actually digging, in areas that had not been previously excavated. These tests revealed a mysterious feature never seen before in Hopewell archaeology, a circular arrangement of posts nearly 60 meters (about 200 feet) in diameter. The Ohio History Connection asked Dr. Robert Riordan, Professor and Chair of the Department of Sociology and Anthropology at Wright State University in Dayton, Ohio to conduct an archaeological investigation in this newly discovered area with the help of his Field School in Archaeology. He began excavations in 2006 and has continued each summer since. At the center of this ring of posts, now referred to as the Moorehead Circle, there lays a shallow basin filled with presumably burned red clay. Currently, there are several research projects based on the work being done at the Moorehead Circle in hopes that we might gain insight into how it was used and, potentially, how Fort Ancient itself was used in prehistory.
On August 1st, 2009, the Dayton Society of Natural History (DSNH), parent organization of the Boonshoft Museum of Discovery and SunWatch Indian Village/Archaeological Park, assumed management of the day-to-day operations at the Fort Ancient Earthworks & Nature Preserve. This partnership between the History Connection and DSNH assures that Fort Ancient will remain a protected piece of American prehistory that is available for the public to enjoy.


Ukhrul, March 23 2015: Deputy Commissioner (DC), Ukhrul Hrisheekesh Arvind Modak Monday inaugurated a newly constructed multipurpose community hall under the Common Facility Centre (CFC) initiative of IFAD Ukhrul in a function held at Langdang village in Ukhrul District.
Located some 12 km North of Ukhrul District Headquarters, Langdang village having a total of 243 households, is one of the beneficiary villages of various rural developmental programmes taken up by IFAD Ukhrul in the district.
Construction of the new CFC hall at a total cost of Rs.14, 95, 000 by Hotnangai NaRM-G, Langdang village with the project contribution of Rs.8, 73, 600 by NERCOMP-IFAD, Ukhrul is one among the agency's initiatives.
DC Modak, who is also the chairman of NERCOMP Ukhrul, dedicated the new facility for the benefits of the villagers in the presence of project manager UDCRMS/NERCOMP-IFAD Tychicus Vashum at 11 am today.
Speaking as the Chief Guest during the function, Modak called upon the residents to put the new hall to good use, while exuding hope that the spacious hall would cater to the varied needs of the villagers for holding meetings, Anganwadi and other local purposes.
He also said that Langdang village has potential for growing owing to its proximity to the district headquarters.
He then suggested that people could get engrossed in agriculture and related activities to enrich themselves economically.
In his speech, project manager Vashum highlighted the importance of convergence in implementation of various developmental programmes in the present day context, while urging the district administration to explore such avenues.
He said that the new CFC has been constructed as part of the IFAD's mission to create infrastructures in the district's rural areas.
Comparing the construction of the same facility at different villages within the district, he felt that there were certain qualitative differences between them.
He then made no bones of the fact that IFAD would not put up with any development partners which compromise on quality in execution of projects.
During the function, Tangkhul cultural show and dance were presented by Langdang elders and youth.
Representatives from various other fraternal NGOs were also present at the inauguration function.
JSSK benefits denied at JNIMS?


My research program focuses on cardiometabolic disease and diabetes-related co-morbidities. As the Chair of the CardioLink Clinical Trials platform, I am conducting a number of clinical trials in diabetes and its complications. The first of these trials, EMPA-Heart, seeks to uncover the mechanism underlying the cardioprotective effects of the SGLT2 inhibitor, empagliflozin, that was reported in the EMPA-REG Outcome study. This trial is in the late stages of recruitment and will report primary outcomes in 2018. The NEWTON CABG trial will assess whether blockade of the PCSK9 receptor in individuals will diabetes can reduce the risk of future cardiac events after bypass surgery. In the ENABLE-Chiropody trial, persons with diabetes undergoing hemodialysis will undergo a chiropody-based intensive, structured, and evidence-based care program with the aim of lowering the incidence and progression of diabetic foot ulcers and amputations. This initiative is fully supported by a partnership with Diabetes Action Canada which is part of the CIHR-SPOR network. In addition, I oversee a dynamic research lab in the Li Ka Shing Knowledge Institute of St. Michael's Hospital which has a special interest in the role of SGLT2 inhibitors as a potential modulator of endothelial function and atherosclerotic vascular disease. Finally, I am a national lead/steering committee member on three SGLT2 inhibitor trials that are evaluating the impact of this class of drugs on heart failure.
Honourary degrees from the Universities of Toronto, Zagreb, Saskatchewan, McMaster and Karolinska Institute.
Dr. Vranic's discoveries concerning the relationship between exercise, stress and diabetes have had an important impact on individuals suffering from this disease. His ground-breaking studies have opened many doors for diabetics, including participation in Olympic Games. His development of tracer methods revolutionized the field of glucose turnover in physiology and diabetes, paving the way for clinical investigation leading to the translation of basic science to practice. He led the first international symposium on exercise and diabetes, which had a large impact, facilitating the evidence of epidemiologists that exercise can prevent diabetes. His discovery of extrapancreatic glucagon changed existing dogma that pancreatic hormone is synthesized in only one gland, and provided evidence about the importance of glucagon in diabetes. He demonstrated mechanisms whereby the muscle and the liver are protected against hyperglycemia and therefore, against diabetic complications. He pioneered the concept that some stresses are beneficial for diabetes and is currently developing methods to prevent hypoglycemia in type 1 diabetes. He has a patent regarding the prevention of hypoglycemia in insulin-treated diabetic patients. This topic is presently researched between four different institutions. He has trained a large number of graduate and post-doctoral students, and has widely collaborated with younger scientists, some of whom are presently world-leaders in diabetes research. Three of his students were Presidents of the Canadian, American, and Japanese Diabetes Associations.
This blend maximizes viscosity as a driver of physiological effectiveness in the management of diabetes and reduction of blood lipids. Dr. Vuksan holds Canadian & USA patents for this discovery. His research on fiber blend has attracted the attention of the food industry, and the product is now commercially available worldwide.
The consumption of this ancient Aztec seeds high omega-3/fiber rich, improved conventional and novel risk factors for cardiovascular disease in those with diabetes. Dr. Vuksan's studies were the first to demonstrate health benefits of these seeds in humans, gaining the attention internationally of the research community and popular press. Economic analysis on exports by main producers of Salvia Hispanica, Mexico, Argentina and Australia, show a major surge in export of the seeds coinciding with his publications in 2007/2010. His research has thus ignited significant economic benefits to countries producing the seeds and the local farmers have led to increased human consumption worldwide.
Ginseng was hardly known for its metabolic benefits in humans until Dr. Vuksan's studies in early 2000. His group was the first to demonstrate potential hypoglycaemic efficacy and safety of ginseng. His investigations of the potential of medicinal herbs and ginseng in particular have received international recognitions.
Research in the Wang lab is focused on understanding the biology the pancreatic islet, im particular the regulation of islet cell secretion and function. We are also studying the biology of GLP-1, an incretin hormone released from gut cell in response to feeding. Among patients with diabetes, while the production of insulin is insufficient, release of GLP-1 is reduced. However, glucagon and glucose production is too high. While seeking a means to increase pancreatic insulin production, enhance GLP-1 action, we are also studying the signaling and molecular control of islet cell-cell interactions in regulating islet beta-cell function and glucose homeostasis during the development of diabetes. Our research is fundamental and translational, aiming at developing new therapeutic strategies that could enable patients with diabetes to permanently manage the disease and effectively avoid its associated complications.
My research focuses on improving health and performance under extreme conditions such as respiratory and muscle diseases including cystic fibrosis, metabolic syndrome, and cancer in a pediatric population. We use advanced magnetic resonance imaging/spectroscopy techniques to help elucidate pathophysiologies of exercise intolerance in chronic disease. Recently I was involved in a project that evaluated Turner Syndrome (TS) in female adolescences. TS is associated with an increased lifetime risk of type 2 diabetes and cardiovascular disease, and we compared cardiometabolic risk factors and measures of subcutaneous, visceral adipose tissue and intra-myocellular lipid between those with TS and healthy controls. In this study we concluded that adolescent TS girls exhibit more cardiometabolic risk factors and reduced beta cell function compared with controls.
I am interested in further exploring how the presence of type 2 diabetes might contribute to exercise intolerance/reduced physical function in other chronic diseases. My research team is working to elucidate the pathophysiology of exercise intolerance in children following bone marrow transplant (BMT) – a population who is at a high risk of developing metabolic syndrome/type 2 diabetes. We plan to determine how the presence of metabolic syndrome/type 2 diabetes might influence cardiac and muscle metabolism in children post-BMT.
The zebrafish has emerged as an important vertebrate model organism for annotation of gene function, modeling human disease and drug discovery. My lab is developing a few projects to: (1) create fluorescent zebrafish models to genetically label pancreatic beta and alpha cells, and then perform lineage specific cell ablation and study their regeneration and relationship; (2) generate novel zebrafish models for anti-diabetic compound screen. We are currently creating a reporter zebrafish strain for monitoring Phosphoenolpyruvate Carboxykinase (PEPCK) activity, a rate-limiting enzyme in gluconeogenesis. Compounds modulating PEPCK activities in zebrafish and may be developed as novel potent anti-diabetic drugs.
One of the changes commonly observed in patients with type I Diabetes, is impaired vision. As Director of a world class pediatric visual Electrophysiology unit I have the tools to describe visual processing using the latest technologies for objective neuro-retinal assessment. My lab has made significant contributions to investigations defining the earliest neuro-marker of visual and ocular dysfunction in adolescents with Type 1 Diabetes (T1D). We found that chromatic mechanisms are disrupted at puberty in children with T1D (Invest Ophthalmol Vis Sci. 2005). Later we identified that short-wavelength retinal processing was disrupted in adolescence with T1D: McFarlane, et al. (2012), Invest Ophthalmol Vis Sci 53(2): 741-748. In later disease diabetes presents clinically as retinal lesions in isolated areas; therefore we focused our studies to early signs of damage in distinct retinal areas. Using multifocal electroretinography we found deficits in localized retinal processing: Lakhani, et al., (2010) "Insufficient long-term glycaemia control is associated with multifocal ERG defects in adolescents with Type 1 Diabetes". Invest Ophthalmol Vis Sci. 51(10):5297-303. Recently we reported specific patterns of retinal deficits: Tan, et al., (Invest Ophthalmol Vis Sci. 2014) "Localizing Functional Damage in the Neural Retina of Adolescents and Young Adults with Type 1 Diabetes," Invest. Ophthalmol. Vis. Sci.. 44 (4): 2432-41 We are currently the first to report localized functional disturbance on the integrity of cone photoreceptors in children with T1D using multi-model adaptive optics imaging: Tan, W., et al., Functional and Structural Cone Abnormalities in Adolescents with Type 1 Diabetes, IOVS 2012; 53: ARVO E-Abstract 371.
Our research is focussed on developing novel strategies to treat Type1 and Type 2 diabetes using multidisciplinary approaches, which combine information gained from genetic models of diabetes, genomics/proteomics, molecular biology and cell biology. Defects in pancreatic endocrine function are central factors in the pathology of diabetes. As such, we are currently investigating several avenues of research that explore pancreatic islet function in both healthy and diseased states. These include the role oxidative stress, reactive oxygen species and uncoupling proteins in the development of diabetes. We also explore the roles of membrane bound proteins like transporter, ion channels and receptors on pancreatic islet function. Another major thrust of our research is to work closely with stem cell biologists in Toronto to produce and characterize stem cell-derived beta cells for potential use in treating Type 1 diabetes.
Members of the Wheeler lab have access to state-of-art facilities at both the University of Toronto and the University Health Network at TMDT and have forged collaborations with world-class research teams working in the diabetes field. The laboratory is affiliated with the Endocrinology and Diabetes Research Group in the Department of Physiology at U of Toronto and the Banting and Best Diabetes Centre at UHN. As such the Wheeler lab is an excellent training environment for undergraduates, M.Sc. and Ph.D. candidate as well as post-doctoral fellows and residents interested in diabetes.
TrialNet has 11 clinical centres across Canada.
Our primary research focus is to elucidate immune mediated pathways governing obesity related insulin resistance. Obesity and its major complications, including insulin resistance, are a major global cause of morbidity and mortality, and have reached epidemic proportions. Evidence is mounting that a significant contributing cause of insulin resistance is chronic inflammation in visceral adipose tissue (VAT). This inflammation was initially thought to be driven solely by macrophages of the innate immune system attracted to dying adipocytes in fat. Recently, in collaboration with the Hospital for Sick Children, and StanfordUniversity, we have demonstrated that the adaptive immune system, including T cells, B cells and the antibodies they produce, play a significant and active role in regulating this process. This work has introduced a new "autoimmune" component to obesity related insulin resistance, and has led to new ways in thinking about metabolic disease. We continue to investigate immune mediated mechanisms in obesity and diabetes with the aim of translating our findings to help the many people afflicted by these diseases.
Research involves studies of pathological changes in the brain related to learning and memory. Specifically, diabetes can cause reduction in rate of neurogenesis in adult brain, which in turn, can lead to impaired learning and memory. Specific signals leading to impairment of neurogenesis and ways of preventing or compensating for impaired memory are under investigation.
The major research focus in the Woo laboratory is to elucidate molecular mechanisms that determine pathogenesis of insulin resistance and type 2 diabetes. Our research interests include elucidating mechanisms of islet apoptosis and survival in physiological and diabetic states. We are interested in many of the fundamental genes involved in cell survival and apoptosis such as caspases, tumour suppressors and oncogenes. Many of these fundamental genes have essential physiological roles in metabolic tissues such as liver, muscle, adipose tissue, and the pancreatic islets. Using genetically engineered mice, we examine the whole body physiology as well as take biological, biochemical and molecular approaches to define physiological roles in specific tissues, in addition to defining its potential pathogenic role in diabetes. These approaches to clarify tissue-specific molecular mechanisms have wide implications for treatment of both type 1 and type 2 diabetes.
Our laboratory is primarily interested in the abrogation of signal transduction pathways in human disease, in particular the phosphatidylinositol 3′ kinase pathway and the Wnt pathway. Both are implicated in cancer and diabetes. We are studying several protein kinase components of these pathways, such as Protein Kinase B (PKB/Akt), Serum and Glucocorticoid-inducible Kinase 3 (SGK3) and Glycogen Synthase Kinase-3 (GSK-3). GSK-3 is associated with Alzheimer's Disease, bipolar disorder and type II diabetes. There are two mammalian genes for GSK-3, termed alpha and beta and we have generated both conventional and tissue-specific knockout mice strains of each. For example, we have generated mice that specifically lack GSK-3beta in either skeletal muscle and have characterized the insulin and glucose tolerances of these animals. GSK-3 is inhibited by insulin signalling and thus the knockouts are providing insight into the utility of GSK-3 inhibitors as sensitizers for insulin-resistant patients. We are also identifying novel targets for GSK-3 (and other protein kinases) which will help us understand the molecular mechanisms by which GSK-3 influences blood glucose responses.
Study of mechanisms underlying complications of diabetes, in particular kidney fibrosis.
Advanced pharmaceutics and drug delivery. Our research interests and activities related to diabetes treatment include microencapsulation of enzymes, therapeutic hormones and polypeptides; artificial islet cells; nanomaterials such as bio-inorganic, polymer-metal and polymer-lipid hybrid nanoparticles and nanocomposite membranes; nanoparticulate contrast agents and fluorophores for in vitro/in vivo imaging; ROS-regulating systems; "intelligent" drug delivery systems for self-regulated drug delivery; nanotechnology-enabled glucose-responsive closed-loop insulin delivery implants for diabetic research animals and for clinical treatment.
Our primary focus is in single molecule biophysics and specifically the interaction between biomolecules, including membrane receptors. Our primary research tools are single molecule microscopies (confocal / TIRF / atomic force) coupled with high-resolution infrared and fluorescence spectroscopies. We are motivated by a keen interest in the functional integration of these techniques to enable single molecule imaging in live cells. Our past efforts have included direct imaging of isolated insulin receptors in model membranes, single molecule force spectroscopy of insulin self-association, and mapping of glucacon fibril formation, and characterization of insulin crystallization by atomic force microscopy.
My research interests lie in the role of patient and clinician behaviour change in knowledge translation. I am particularly interested in the development of innovative strategies for continuing professional development and patient education in chronic disease management, specifically diabetes care.
My research program is focussed on the development of novel therapies targeting the fibrosis and endothelial injury that occurs in the diabetic kidney. As a nephrology clinician scientist at St. Michael's Hospital, my research involves the use of both cell biology and animal models of diabetic injury. Current work in the lab is devoted to understanding: (1) mechanisms of diabetic endothelial injury, including both the early glomerular angiogenesis and the later capillary rarefaction that occurs in diabetes, (2) novel mechanisms of fibroblast activation in diabetes, including the relevance of fibroblast cytoskeletal rearrangements in this process.
Studies evaluating metabolic and pharmacologic interventions to prevent diabetes complications.


Owenduff catchment. 31/07/86; Mayo; 1,382 ha; 54°03'N 009°40'W. Part of the most extensive remaining blanket bog complex in Ireland, the site includes lowland and mountain blanket bog, wet heath and cliffs in the surrounding lowlands. There are several mountain valley lakes and rock basin lakes with many pool complexes. Unimproved grassland and numerous wetland vegetation types occur along watercourses. The site supports a small wintering flock of the globally vulnerable goose Anser albifrons flavirostris and a nesting population of Pluvialis apricaria. Ramsar site no. 336.


Hypertension induces a compensatory thickening of the ventricular wall in an attempt to normalize wall stress, which results in LV concentric hypertrophy, which in turn decreases LV compliance and LV diastolic filling, resulting in Heart Failure. Overall the prevalence of hypertension appears to be around 30 – 45% of the general population.1 In Indonesia, Hypertension prevalence was 25,8% as shown by Data Riset Kesehatan Dasar (Riskesdas) Indonesia in 2013.2 10% global healthcare expenditure attributed to hypertension, and global annual worldwide cost of treating hypertension is $370 billion. However, hypertension often treated improperly, failing to achieve BP goal that could lead to the development of Heart Failure. Hypertension induces a compensatory thickening of the ventricular wall in an attempt to normalize wall stress, which results in LV concentric hypertrophy, which in turn decreases LV compliance and LV diastolic filling. Heart failure is characterized by changes in many neurohormonal mechanisms, but notably activation of the renin angiotensin aldosterone system (RAAS) and inhibition of these two systems is the primary target of current treatment. Beta-blockers have been shown to reduce adrenergic drive, improve autonomic balance, and reduce ventricular wall stress. Nebivolol is a third-generation, long-acting and highly selective β1 adrenoreceptor antagonist that also exhibits nitric oxide (NO)-mediated vasodilatory effects via β3 receptor agonist and reduces oxidative stress. Study in hypertensive patients has shown nebivolol as an effective and well tolerated antihypertensive therapy and further study in elderly heart failure patients has shown that nebivolol is not only a potent beta-blockade agent in heart failure with reduced ejection fraction (HFrEF), but also showing similar effect in heart failure with preserved EF (HFpEF).
Conclution: Hypertension is the most prevalence cause of Heart Failure and nebivolol is not only an effective antihypertensive agent, but also a potent beta-blockade agent for heart failure.


The goal of the hack is mostly assumed to be an attempt to obtain contact information and send fraudulent solicitations to current and former subscribers. Dow Jones Chief Executive William Lewis mentioned in the letter written to customers yesterday that a potential breach had been reported by law-enforcement in late July this year. However, it was confirmed only post investigation that unauthorised access to company records had begun as early as August 2012 and lasted right till July 2015. To read the full letter by William Lewis, click here.
This cyber-attack does not come across as an isolated incident but more like part of a larger scheme that targets other private firms and companies as well. With names like Ashley Madison and Sony that have already been victims of cyber crime, let's see which company lands itself next in hacking trouble.


text:
EU's Foreign Minister confirms her support of a UN Parliamentary Assembly
Remarks of the EU's High Representative at an event in Rome
Speaking at an event in Rome, the European Union's High Representative for Foreign Affairs and Vice-President of the European Commission, Federica Mogherini, expressed her continued support for the proposal of a United Nations Parliamentary Assembly, UNPA.
Federica Mogherini speaking in Rome
Image: L. Puccini
"I have not changed my mind since I was a member of the Italian Parliament: a UN Parliamentary Assembly could be a very useful tool," Mrs. Mogherini said in Rome. She continued: "I don't know how realistic it is to conceive its creation in the short run. But I think that a UNPA would help the UN to be more effective and help the system of global governance to create connections with an active and responsible citizenship. Indeed, a UN Parliamentary Assembly could strengthen the link between a system of global governance, which is remote by definition, and a citizenship that includes a global dimension."
As a member of the Italian Parliament Mrs. Mogherini endorsed the international appeal for a UNPA and authored a parliamentary motion on the subject. In a message on the occasion of the first Global Week of Action for a World Parliament in October 2014, Mrs. Mogherini stated that "the answer that is provided by the cooperation of nation-states is often no longer enough" to respond to "the globalization of economy and finance, the mounting imbalance in the distribution of wealth, or asymmetric threats to international security." She stressed that "There's an increased urgency that political institutions and instruments of participation and democracy also go through a process of globalization. That's why I support the establishment of a UN Parliamentary Assembly."
At the event in Rome, Mrs. Mogherini explained that "I'm a passionate advocate of parliamentary assemblies. I think that parliamentary diplomacy is one of the most powerful tools in the world. I believed it when I was a member of the Italian parliament, and I was even more convinced when I took on my successive responsibilities because I saw the need for a direct connection between citizen representation and the increasing need of international consensus. I experienced this at NATO's Parliamentary Assembly and the Parliamentary Assembly of the Council of Europea, and I see it every day at the European Parliament. Unfortunately, the international and global dimension of parliamentary assemblies are a huge tool whose enormous potential is often denied."
The topic of the event in Rome was EU relations with Latin-America. It was organized on 15 January 2016 by the Istituto Affari Internazionali
Top image: Istituto Affari Internazionali/Leonardo Puccini
Tags: European Union


text:
Zynerba Pharmaceuticals Reports Third Quarter 2016 Financial Results and Operational Highlights
DEVON, Pa., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today reported financial results for the third quarter ended September 30, 2016 and provided an overview of recent operational highlights.
"The third quarter was marked by significant advancement of our lead development candidate, ZYN002 CBD gel," said Armando Anido, Chairman and CEO. "We initiated randomization and dosing, and are continuing to enroll patients into the STAR 1 refractory epilepsy clinical trial. We also initiated the STOP trial, which will evaluate ZYN002 CBD gel in patients with knee pain associated with osteoarthritis. We look forward to initiating a third Phase 2 clinical trial of ZYN002 CBD gel in patients with Fragile X Syndrome by year-end. We expect to report top line results of all three Phase 2 clinical trials in the first half of 2017."
Highlights from the Third Quarter 2016 & Recent Developments
Began Dosing of First Patients in STAR 1 Clinical Trial for the Treatment of Adult Epilepsy
In August, Zynerba began dosing patients in STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy), a randomized, multi-center, multi-dose Phase 2 clinical trial that will evaluate 97.5 mg or 195 mg of CBD in ZYN002 4.2% gel or placebo every 12 hours in approximately 180 adult refractory epilepsy patients with focal seizures. The primary endpoint will assess the median percentage change in seizure frequency over the 12-week treatment period versus baseline. Safety and tolerability will also be assessed.
Initiated STAR 2 Open-Label Extension for the Treatment of Adult Epilepsy
In November, Zynerba initiated an open-label clinical trial in adult epilepsy patients with refractory focal seizures who complete the STAR 1 study. Patients will receive treatment with ZYN002 for up to 52-weeks. The open-label clinical trial is designed to support long-term safety and tolerability of ZYN002 CBD gel.
Launched Phase 2 STOP Clinical Trial for the Treatment of Osteoarthritis (OA)
In September, Zynerba initiated the STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis) trial, a multi-center, placebo-controlled, Phase 2 clinical trial that will evaluate 125 mg or 250 mg of CBD in ZYN002 4.2% gel or placebo twice daily in approximately 300 patients with knee pain due to OA. The primary endpoint is the change from baseline in the weekly mean of the 24-hour average worst pain score.
Updated Progress with ZYN001 pro-drug of THC Patch
In October, the Company announced that it is working with LTS Lohmann Therapie-Systeme AG, a market leader in transdermal therapeutic solutions, to optimize the formulation of ZYN001 into a state of the art drug-adhesive matrix transdermal patch. ZYN001 is a patent-protected pro-drug of THC being developed for the treatment of fibromyalgia and peripheral neuropathic pain.
Upcoming Events in the Fourth Quarter of 2016
At the American Society of Epilepsy meeting to be held in Houston, TX, from December 2-6, Zynerba will present two posters highlighting safety and tolerability and cognitive and mood effects for ZYN002.
Zynerba will host a Clinical Research Day on December 15th in New York City featuring distinguished experts who will discuss the role of cannabinoid-based treatments in epilepsy, osteoarthritis and Fragile X syndrome.
Upcoming Clinical Milestones
Zynerba plans to initiate a third Phase 2 clinical trial of ZYN002 in patients with Fragile X syndrome (FXS) by year-end 2016.
Top line results of three Phase 2 clinical trials in refractory epilepsy, OA and FXS are expected in the first half of 2017.
ZYN001 pro-drug of THC Patch
Zynerba expects to initiate Phase 1 clinical trials to evaluate the pharmacokinetic profile and tolerability of ZYN001 in healthy volunteers in the first half of 2017.
Phase 2 clinical trials in the treatment of fibromyalgia and peripheral neuropathic pain are planned to begin in the second half of 2017.
Third Quarter 2016 Financial Results
As of September 30, 2016, cash and cash equivalents were $31.8 million, compared to $32.1 million as of June 30, 2016. In September 2016, the Company entered into an Open Market Sales Agreement with Jefferies LLC pursuant to which, as of November 11, 2016, the Company sold and issued 753,799 shares of its common stock in the open market at a weighted average selling price of $13.38 per share, for net proceeds of $9.5 million, $5.3 million of which were received and included in cash and cash equivalents as of September 30, 2016. The remaining $4.2 million of net proceeds was received after September 30, 2016 and will be included in the fourth quarter financial statements.
Research and development expenses for the third quarter of 2016 were $4.5 million, including non-cash stock-based compensation of $0.3 million. General and administrative expenses for the third quarter of 2016 were $1.5 million, including non-cash stock-based compensation expense of $0.5 million. Net loss for the third quarter of 2016 was $6.0 million with basic and diluted net loss per share of ($0.67).
Financial Outlook
Management believes that the Company's available funds, including proceeds from the sale of common stock received through November 11, 2016, are sufficient to develop five Phase 3 ready programs and these resources are sufficient to fund operations and capital requirements into 2018.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Zynerba is developing therapeutic candidates based on proprietary transdermal technologies that, if successfully developed, may allow sustained, consistent and controlled delivery of therapeutic levels of two cannabinoids: cannabidiol (CBD), a non-psychoactive cannabinoid, and tetrahydrocannabinol (THC). Transdermal delivery has the potential to reduce adverse effects associated with oral dosing. ZYN002, the Company's CBD gel, is the first and only synthetic CBD formulated as a patent protected permeation-enhanced gel. In June 2016, the company initiated the Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial of ZYN002 CBD gel in refractory epilepsy patients with focal seizures and has also launched the STAR 2 open-label extension trial which allows patients who complete STAR 1 to receive treatment with ZYN002 gel for up to 52 weeks. In August 2016, the Phase 2 STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis) clinical trial in patients with knee pain due to OA was initiated. A Phase 2 clinical trial in Fragile X syndrome (FXS) is expected to initiate in the second half of 2016. Zynerba is also developing ZYN001, which utilizes a synthetically manufactured pro-drug of THC. A Phase 1 clinical trial for ZYN001 is planned to begin in the first half of 2017. Learn more at www.zynerba.com and follow the Company on Twitter at @ZynerbaPharma.
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. For example, there can be no guarantee that the Company will obtain approval for ZYN002 or ZYN001 from the U.S. Food and Drug Administration (FDA) or foreign regulatory authorities; even if ZYN002 or ZYN001 are approved, the Company may not be able to obtain the label claims that it is seeking from the FDA. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the success, cost and timing of the Company's product development activities, studies and clinical trials; the success of competing products that are or become available; the Company's ability to commercialize its product candidates; the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates; and the Company's expectations regarding its ability to obtain and adequately maintain sufficient intellectual property protection for its product candidates. These and other risks are described in the Company's periodic reports, including the annual report on Form 10K, quarterly reports on Form 10Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
ZYNERBA PHARMACEUTICALS, INC.
Three months ended Nine months ended
September 30, 2016 September 30, 2015 September 30, 2016 September 30, 2015
Revenue $ - $ 199,407 $ 7,250 $ 229,625
Research and development 4,504,097 2,271,968 11,880,264 4,136,659
General and administrative 1,493,461 1,922,755 4,649,948 3,208,003
Total operating expenses 5,997,558 4,194,723 16,530,212 7,344,662
Loss from operations (5,997,558 ) (3,995,316 ) (16,522,962 ) (7,115,037 )
Interest income 22,747 1,572 53,243 2,948
Foreign exchange loss (6,270 ) - (49,668 )
Total other income (expense) 16,477 1,572 3,575 2,948
Loss before income taxes (5,981,081 ) (3,993,744 ) (16,519,387 ) (7,112,089 )
Income tax benefit - - (27,543 ) -
Net loss $ (5,981,081 ) $ (3,993,744 ) $ (16,491,844 ) $ (7,112,089 )
Net loss per share - basic and diluted $ (0.67 ) $ (0.66 ) $ (1.86 ) $ (2.37 )
Basic and diluted weighted average shares outstanding 8,912,508 6,045,211 8,865,854 2,998,480
Non-cash stock-based compensation included above:
Research and development $ 292,385 $ 297,169 $ 916,036 $ 297,169
General and administrative 513,019 539,655 1,465,906 539,655
Total $ 805,404 $ 836,824 $ 2,381,942 $ 836,824
ZYNERBA PHARAMCEUTICALS, INC.
September 30, 2016 December 31, 2015
Cash and cash equivalents $ 31,780,773 $ 41,513,060
Incentive and tax receivables 2,281,205 356,718
Prepaid expenses and other current assets 1,464,564 1,545,917
Total current assets 35,526,542 43,415,695
Property and equipment, net 304,141 227,646
Other assets 463,600 200
Total assets $ 36,294,283 $ 43,643,541
Accounts payable $ 1,694,470 $ 823,401
Accrued expenses 2,882,060 2,272,991
Deferred grant revenue 370,575 841,225
Deferred grant revenue, long-term 463,400 —
Common stock 9,628 9,200
Total stockholders' equity 30,883,778 39,705,924
Total liabilities and stockholders' equity $ 36,294,283 $ 43,643,541
Jim Fickenscher, CFO and VP, Corporate Development
Zynerba Pharmaceuticals
Fickenscherj@zynerba.com
Kimberly MinarovichArgot Partners
kimberly@argotpartners.com
Eliza SchleifsteinArgot Partners
eliza@argotpartners.com


There are a number of different models and years that use the same r/r's as ours. To find out which other models apply, go here, http://www.powersportspro.com/pages/...d/default.aspx , select Honda in the quick part look up box, plug 31600-MS2-601 in the "Search For" box, then hit the "Quick Look-up" button. Can come in handy if looking for an R?R on ebay or elsewhere. I just bought one on ebay from a 750 Nighthawk for $34 shipped.
That's a cool find, Paco. Could come in real handy.
Where is the Regulator/ Rectifier?


text:
Research › Research Areas › Evidence-Based Medicine
Front Row: Cory vans, Michelle Eder, Nadia Redmond, Tracy Beil, Jennifer Lin, Elizabeth O'Connor, Beth Webber, Leslie Perdue
Back Row: Rachel Thomas, Debra Burch, Megan Iacocca, Allea Martin, Carrie Patnode, Jillian Henderson, Erin Coppola, Caitlyn Senger, Sarah Bean
The Kaiser Permanente Evidence-based Practice Center (KP EPC) is one of 13 centers nationwide to be designated as an official EPC by the federal Agency for Healthcare Research and Quality (AHRQ).
The EPCs synthesize available scientific evidence on health care topics by conducting evidence reports, including systematic reviews, comparative effectiveness reviews, technical briefs, technology assessments, modeling, decision-analyses, and cost-effective analyses. These evidence reports are used to guide health care decision-making by clinicians, patients, policymakers, researchers, and payers. The EPCs also conduct research to advance the methodology of systematic reviews.
The KP EPC involves over 75 researchers from the Kaiser Permanente Center for Health Research, Kaiser Permanente Washington Health Research Institute, and HealthPartners Institute for Education and Research. The KP EPC is headquartered in Portland, Oregon at the Kaiser Permanente Center for Health Research and directed by Jennifer S. Lin, MD, MCR.
Investigators at the Kaiser Permanente EPC have extensive experience in key cross-cutting areas, such as systematic reviews in preventive services and genomic test evaluations, and focused expertise in methods development. Our investigators have completed systematic reviews or methods-related projects for many different groups, including the Effective Health Care Program, the US Preventive Services Task Force (USPSTF), the Centers for Disease Control and Prevention (CDC), and the National Cancer Institute (NCI). KP EPC researchers have also played a key role in the Scientific Resource Center work undertaken for major evidence-based programs such as the Effective Health Care Program, USPSTF, and Evaluation of Genomic Applications in Practice and Prevention (EGAPP).
EPC Contacts
Jennifer S. Lin, MD, MCR
Jennifer.S.Lin@kpchr.org
Tracy Beil
EPC Project Director
Tracy.Beil@kpchr.org
Debra Burch
Assistant to EPC Director
Debra.Burch@kpchr.org
Center for Health Research,
Kaiser Permanente Northwest
3800 N. Interstate Ave.
A Brief History of the EPC
Under the leadership of Evelyn Whitlock, MD, MPH, the Kaiser Permanente Center for Health Research was a founding partner in the Oregon Evidence-based Practice Center (EPC), one of the 12 original EPCs initially designated in 1997 by the Agency for Healthcare Research and Quality (AHRQ). Over 18 years, we have built our EPC experience into a vibrant research enterprise employing a stable staff of close to 20 dedicated systematic reviewers.
In 2012, we established the Kaiser Permanente EPC (KP EPC), which has since engaged over 50 researchers and staff on more than 30 systematic reviews or methods projects. After 10 years as a lead investigator in our EPC, and three years as associate director, Dr. Jennifer S. Lin became the EPC director in 2016.
Independence & Conflicts of Interest
We conduct our EPC work as part of the extensive, externally-funded, non-proprietary research that is conducted in affiliation with the Kaiser Permanente Center for Health Research. Since the KP EPC's funding and operations are within autonomous research centers, our EPC Investigators' research agendas and published findings are neither determined nor influenced by the Kaiser Permanente payer or delivery system leaders and administrators. In addition, we have policies and procedures in place to ensure that no undue conflict of interest affects the perception or actual conduct of our work. Potential conflicts of interest are clearly identified and disclosed, and individuals with potential conflicts of interest (i.e., those who could gain a personal financial or other benefit from a particular scientific decision) are not allowed to influence any of the scientific decisions or access the results before publication.


Pleurisy: Infection from the pleurae, this filters around the lungs. Indications consist of suffering while in the box, torso tenderness, cough, and also lack of breath. Belly pain is usually sharp as well as provoked by way of inhaling. Your physician could perceive having a stethoscope this rubbing created with the take off of these two irritated cellular layers involving pleurae by using each one breathing. What may cause pleurisy include things like lung bacterial contamination, collagen general diseases such as lupus plus rheumatoid arthritis symptoms, cancer of the lung or even pleura, heart failure, lung embolism (blood clot inside the voice), impediment associated with lymph options, trauma including roast bone injuries, medications for instance Dilantin, pancreatitis, along with cirrhosis of the liver. Removing pleural substance, if provide, having a filling device as well as syringe is key inside detecting the cause of pleurisy and may as well relieve the pain sensation plus bouts of dizziness associated with pleurisy. If your liquid is actually inflammed, therapy will involve use of medicines as well as water flow of the material. Inside extreme circumstances, through which you will discover large amounts involving purulence and scar tissue formation (adhesions), there will probably be an excuse for decortication (beginning this pleural space along with removing helpings of one or maybe a couple of bones in order to obvious scar tissue and take away sanies plus particles). Often called pleuritis.
Health Thesaurus Descriptions Some sort of - Z .
Workout Prime Chosen lifestyle Variable to get Alzheimer's Elimination?
Florastor, Florastor Children (saccharomyces boulardii lyo) Pharmaceutical Unwanted side effects, Communications, and also Prescription medication Facts about World wide-Medicalsearch.


text:
Q: SQL Server table design and using SqlBulkCopy to insert data I just need a suggestion on making the best use of SqlBulkCopy.
Say I have a table as shown below
    Type BidNumber HQregion Services PrimaryExec Value
    --------------------------------------------------
          22        USA      Some     None         33
          24        Europe   None     Delta        44
    SL    22        USA      Some     Tango        39
    GV    44        Mexico   Delta    Charlie      33
    Time  22        India    Charlie  None         33

There can be say about 100k entries with empty Type column 100k with SL with some same data points as empty but some different and I am using SqlBulkCopy to copy data from Excel files into this table.
I was wondering if I should break the table into multiple tables which have the same exact columns but differentiate based on the type so one table for say MainData, another for SLData and GVData and then use SqlBulkCopy to just insert data into specific tables. Is that a bad design with multiple tables when only one column data is different and is that going to be any efficient when using bulk copy since I have to delete the data before inserting and it's a nightly process.
So the final structure would be:
Main Table
BidNumber HQregion Services PrimaryExec Value

SL Table
BidNumber HQregion Services PrimaryExec Value

GV Table
BidNumber HQregion Services PrimaryExec Value

Time Table
BidNumber HQregion Services PrimaryExec Value

Thanks

A: You overcomplicate things. 100k is small for sql bulk copy. Like tiny. It is a size I would expect to upload in a second or so.

A: If for future reasons of increasing size you would like to divide the excels, I would suggest you to keep the excel as it is and bulk copy the complete data into staging table and then multicast the specific filtered data to corresponding tables.

redpajama_set_name: RedPajamaStackExchange


—Cambridge, MA-based vaccine developer Genocea Biosciences (NASDAQ: GNCA) was the first local biotech to price this week, and it got a lukewarm response from Wall Street. Genocea priced its IPO at $12 per share, at the low end of its projected $12 to $14 per share range, and raised $66 million by selling 5.5 million shares to public investors. Genocea opened up on the Nasdaq on Wednesday at $11.90, and finished its first trading day at $11.
—Cambridge-based Eleven Biotherapeutics (NASDAQ: EBIO) followed suit a day later, and had a tougher time. Eleven priced its offering at $10 per share, well below the $13 to $15 it initially planned to sell its shares at. It also upsized its offering to 5 million shares from the original 4.3 million. All told, the company, which is developing a drug for dry eye disease among other ophthalmic drugs, raised $50 million from the IPO before discounts due to underwriters. It did inch up in its first day of trading, however. Shares of Eleven opened at $10.40 apiece and closed at $10.85.
—Some of the East Coast's biggest pharmaceutical companies, including New York-based Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY), Cambridge-based Biogen Idec (NASDAQ: BIIB), Whitehouse Station, NJ-based Merck (NYSE: MRK) and others joined up as part of a deal with the National Institutes of Health to help speed the discovery of potential drugs for Alzheimer's, Type 2 diabetes, rheumatoid arthritis, and lupus. The companies will invest a total of $230 million over five years as part of the collaboration, called the Accelerating Medicines Partnership. Each partner has to share their data and agree to not use any discovery for their own commercial gain until the AMP makes the data public.
—Merck was part of another big partnership this week as well, announcing plans to join with Pfizer, Thousand Oaks, CA-based Amgen (NASDSAQ: AMGN), and Wilmington, DE-based Incyte (NASDAQ: INCY) to run several combination studies using its experimental cancer antibody drug MRK-3475. Those new studies will combine Merck's drug with Pfizer's axitinib (Inlyta), Incyte's experimental immunotherapy drug INCB24360, and Amgen's talimogene laherparepvec, which was acquired in its 2011 buyout of BioVex.
—Boston and San Francisco, CA-based life science investment firm Clarus Ventures is looking to raise $375 million for its third fund, Clarus Lifesciences III, according to an SEC filing.
— Biogen was cleared this week to sell its oral multiple sclerosis drug, dimethyl fumarate (Tecfidera), in Europe. The drug was first approved in the U.S. in March, and has since been green-lighted in Canada and Australia as well. Biogen plans to begin selling the MS drug in certain European countries in the coming weeks. The drug generated $398 million in sales in the fourth quarter of 2013 and is expected to break $1 billion in sales total for its first year on the market.
—Cambridge-based Agios Pharmaceuticals (NASDAQ: AGIO) exercised its option to buy back the U.S. rights to its experimental cancer drug AG-120 from its Summit, NJ-based partner Celgene (NASDAQ: CELG). Agios got that option as part of the big collaboration deal the two companies signed in 2010. Celgene still has rights to AG-120 in the rest of the world.
—New York-based Dipexium Pharmaceuticals, which is developing an antibiotic for diabetic foot ulcers, plans to raise up to $35 million through an IPO. It'll list on the Nasdaq under the ticker symbol "DPRX" if it goes public.
—Longtime Genzyme executive Frederic Chereau is taking flight for San Diego, where he'll become the president and chief operating officer of aTyr Pharma. Chereau spent a decade at Genzyme before taking the head gig at Cambridge-based startup Pervasis Therapeutics. When Pervasis was acquired by Shire in 2012, Chereau stayed on board and was in charge of the company's global angioedema franchise.
—Cambridge and San Diego-based Sialix raised $1.2 million in angel-led financing from Boston Harbor Angels, Mass Medic Angels, Launchpad Angels, and others. Sialix is developing antibodies that target glycans found on the surface of tumor cells. Xconomy profiled the company in early 2013.


"Kjartansson draws on the entire arc of art in his performative practice. The history of film, music, theatre, visual culture and literature finds its way into his video installations, durational performances, drawing and painting. Pretending and staging become key tools in the artist's attempt to convey sincere emotion and offering a genuine experience to the audience. Kjartansson's playful work is full of unique moments where a conflict of the dramatic and the banal culminates in a memorable way. Kjartansson studied at the Iceland Academy of the Arts, he was born in 1976 in Reykjavík, where he still lives today.
From the Luhring Augustine website.


The summer season brings with it a desire for more leisure time and outdoor activities, a little break, or change of pace from our normal program. Strong Start Early Care & Education Day Care provides families in the Trumbull area with a recreational two-month summer camp that continues to incorporate our early childhood education inquiry-based curriculum, which responds to children's curiosity and interests. We will be offering this summer session for 3, 4, and 5-year-olds.
Summertime often means that children press pause when it comes to learning, but that can lead to educational setbacks. With the hands-on activities in Strong Start Day Care's Summer Session, children keep on learning all summer long. Sure, we shift gears to more play-oriented learning, but we are believe that our inquiry-based curriculum can be used effectively in play. In fact, children's play time is the perfect time to incorporate learning because it's a full-body experience and this is a great way to learn. When children use all their senses to learn a new lesson, they learn it more completely. Playing also gives children the chance to tap in to their creativity and when developed creativity adds extra value to every new task they tackle.
Sign up your 3, 4, or 5 year old for Strong Start Day Care's Summer Session for a summer of fun and learning!


A.A. pamphlet "A Newcomer Asks"
Also see our page "For Newcomers" for more information.
See the "Upcoming Meetings" list in the left sidebar.
See the On-Line Local Meeting Schedule for Milwaukie, Clackamas, West Linn, Oregon City, Canby, Molalla & surrounding areas.
Download a printable Meeting Schedule in PDF format.
Tradition 7: "Every A.A. group ought to be fully self supporting , declining outside contributions."
What are my District 15 donations used for? See the printable flyer "Your Donations Explained" - and you can share it with your group.
Service Opportunities - Service is the Secret!
Attend your home group business meeting and get connected.
Become a greeter, a coffee maker, secretary, treasurer.
Come to a District 15 Business Meeting, held monthly on the first Wednesday at 6:45 PM at Atkinson Memorial Church, 6th & John Adams, Oregon City.
Public Information Information/Cooperation with the Professional Community Committee (PI/CPC) activities are about carrying the AA message to schools, community groups, and professionals who may come into contact with alcoholics, such as doctors, nurses, lawyers, and law enforcement personnel.
This position has a lot of support available from an active PI/CPC-North committee, led by the CPC-North and PI-North Chairs from Area 58 and comprised of members representing many of the AA Districts in Portland and northern Oregon.


text:
PSJA Education Foundation raises over $250K during 9th Annual Fundraiser Gala
EDINBURG – Continuing their mission of giving back to the community, members of the PSJA Education Foundation raised more than $250,000 during their 9th Annual Fundraiser Gala held recently at the Bert Ogden Arena.
First founded in 2013, the PSJA Education Foundation, a non-profit 501(c)(3) organization, has helped enhance educational opportunities for the youth and families of PSJA ISD thanks to sponsorships and donations from PSJA Alumni, local businesses, and hundreds of district staff members through payroll deduction.
"Thank you to all individuals and businesses who made contributions and donations," said PSJA Education Foundation President & PSJA School Board Vice-President Jesus "Jesse" Vela, Jr. "We thank you for your generosity, your belief in the Foundation, and in giving back to our students. You help us make a difference."
To date, the PSJA Education Foundation has awarded more than $2.2 million to PSJA ISD students and teachers. Most recently, the Foundation awarded $341,000 in student scholarships and provided continued support to district-wide literacy initiatives with a $17,000 grant to the PSJA Library Services grant during the 2020-2021 school year.
The foundation's primary fundraiser is this annual concert where local businesses and PSJA Alumni donate to the cause. This year the event gave attendees the opportunity to relive the 70s with music from the Australian Bee Gees Show<https://excalibur.mgmresorts.com/en/entertainment/the-australian-bee-gees.html> from Las Vegas. Additionally, attendees got to give during Virtual and Live Silent Auctions. All proceeds benefit students and teachers from Pharr-San Juan-Alamo ISD.
"On behalf of our school district, we are so grateful to everyone in the PSJA Education Foundation for the tremendous effort made every year to raise money for scholarships and grants for our PSJA Family," said PSJA Superintendent Dr. Jorge L. Arredondo. "Thanks to this work, hundreds of our students receive much-needed scholarships to fund their post-secondary education and our teachers are able to get funding for innovative classroom projects."
In support of the PSJA Education Foundation, this year PSJA ISD will once again join forces as a district and community to host the 2nd Annual PSJA Family Virtual Day of Giving<https://alumni.psjaisd.us/g/2nd-annual-psja-family-virtual-day-of-giving> where individuals will be encouraged to make a gift, big or small, to the non-profit in support of these efforts. Individuals can support the cause by making an online donation anytime until November 30, 2021.
The non-profit plans to continue giving back during the 2021-2022 school year. The 2022 PSJA Education Foundation Scholarship Application opens Nov. 1, 2021, deadline is Jan. 30, 2022. All PSJA ISD seniors can apply. For more, visit www.psjaisd.us/foundation<http://www.psjaisd.us/foundation>


Bite size chocolates perfect for all occasssions. Great for a cupcake topper, treats for a party, or just a delicous bite of chocolate.
Sold weight in 1/3 lb. boxes, choose between white, milk or dark chocolates.
Valentine's Day, Weddings, or special occasions.


Located in Woking JDS Compressors Ltd supply, install and design a wide range of compressed air systems in Surrey and the southern counties. From the supply and installation of air compressors in Surrey to associated pipework and maintenance, JDS Compressors Ltd work with you to expand your existing compressed air systems or design larger bespoke compressed air systems to suit your business needs.
JDS Compressors Ltd provide air compressors in Surrey & the UK, as well as carrying out a wide range of air compressor services including air compressor repairs in Berkshire, air compressor maintenance in Woking and air compressor servicing in Guildford, Surrey & across the southern counties..
If you need bespoke compressed air systems in Surrey or anywhere south of Birmingham, please contact JDS Compressors Ltd for a free quotation and one of their highly trained engineers will be happy to help.
JDS Compressors Ltd are specialists in the supply, installation & repair of air compressors in Surrey & across southern England.


text:
Q: Is it semantically correct to use a foreign key to indicate a range? I'm trying to create SQL tables to represent a series of codes used by a third-party API. So far, I have the following tables:
CREATE TABLE ApiCode (
    Id int NOT NULL IDENTITY(1, 1) PRIMARY KEY,
    ResponseCode char(1) NOT NULL,
    ResponseSubCode char(1) NOT NULL,
    ResponseSubSubCode char(1) NULL,
    MinorCodeRangeId int NULL REFERENCES ApiMinorCodeRange,
    Description nvarchar(500)
)
CREATE TABLE ApiMinorCodeRange (
    Id int NOT NULL IDENTITY(1, 1) PRIMARY KEY,

    FromMinorCode char(4) NOT NULL,
    ThruMinorCode char(4) NOT NULL
)
CREATE TABLE ApiMinorCode (
    Code char(4) NOT NULL PRIMARY KEY,
    Description nvarchar(500)
)

The problem is, FromMinorCode and ThruMinorCode can reference codes that don't exist. For example: a range can indicate "5000 - 5ZZZ", but MinorCode might only have entries defined for "5000 - 500A". New codes are added every few months, so the ApiMinorCodeRange table needs to reference the entire range defined in the specs.
I was planning to create foreign keys anyway and mark them as NOCHECK:
ALTER TABLE ApiMinorCodeRange ADD CONSTRAINT FK_FromMinorCode FOREIGN KEY ( FromMinorCode ) REFERENCES ApiMinorCode
ALTER TABLE ApiMinorCodeRange NOCHECK CONSTRAINT FK_FromMinorCode

ALTER TABLE ApiMinorCodeRange ADD CONSTRAINT FK_ThruMinorCode FOREIGN KEY ( ThruMinorCode ) REFERENCES ApiMinorCode
ALTER TABLE ApiMinorCodeRange NOCHECK CONSTRAINT FK_ThruMinorCode

Is this semantically correct?
Will Sql Server's query optimizer be ok with foreign keys that reference an imaginary row?
Should I create a dummy value "5ZZZ - Reserved for future use" instead of setting "NoCheck"?

A: You are trying to implement a business rule that will apply to codes that you have not yet seen.  There is not necessarily a "right" way to do this.
Does a range relationship have to include valid codes?  I don't see why.  For instance, this picture of a set of encyclopedias (remember those?) has ranges on each volume, such as:

*

*A-B

*C

*Sto-Zyg

I don't assume that "sto" is a valid entry in that volume.  I do assume that "stochastic process" would be in the volume.
Why should your codes be different?  More pertinently in your case, the range in your case could (possibly) be '5' to '5ZZZ', even though a '5' might not be a valid code.
And, your rules could end up extending beyond mere ranges.  Perhaps some major code has all minor codes that start with "5" and end with "Z".
My conclusion for the ranges is that requiring a foreign key relationship isn't necessary.
That said, there is another problem that you might want to deal with.  What prevents a code from being in multiple ranges?  I suspect that you would need a trigger to enforce this rule.


text:
tagpages
Pichlmair
critical decision-making in cells
In healthy cells, small amounts of reactive oxygen radicals called ROS are produced in many processes, such as cell respiration or fat burning. While the cell can handle low concentrations, the excessive increase of ROS, for example caused by viral infection, leads to cell death. Researchers from the Max Planck Institute of Biochemistry now report in Nature Immunology about a newly discovered "oxeiptosis" signaling pathway. This pathway measures intracellular ROS concentrations and can thereby control cell death or survival of the cell. Since ROS are produced in a variety of diseases, the researchers believe that this pathway plays an important role in the control of a wide range of pathological processes.
Virus-infected cells produce high concentrations of free oxygen radicals. The Oxeiptosis pathway is activated in these cells and leads to controlled cell death.
Monika Krause © Max Planck Institute of Biochemistry
Living and dying is one of the most existential questions of a society. How to regulate life and death in cells, the smallest unit of life, is investigated by many scientists. A number of well-studied signaling pathways are known that lead to so-called "programmed cell death" that can be triggered through integration of stimuli from outside or inside the cell. The so-called "programmed cell death" can be triggered by a number of well-studied signalling pathways, which integrate intracellular and external stimuli. Depending on the exact way a cell dies, an immune reaction may also be triggered.
Reactive oxygen species (ROS) are known activators of cell death. ROS are formed in healthy and abnormally altered cells and function in a dose-dependent manner according to the quote from Paracelsus: "The dose makes the poison". Oxygen radicals can have destructive effects on cells when accumulating at high doses. Researchers from the research group of Andreas Pichlmair "Innate Immunity" at the Max Planck Institute of Biochemistry now show that the protein molecule KEAP1 can sense an increased amount of ROS and initiate a novel form of controlled cell death.
Oxeiptosis - oxygen radicals lead to controlled cell death
"In general, it was known that KEAP1 functions as a ROS sensor," explains Pichlmair. "At low levels of ROS, KEAP1 changes its structure to activate the production of cell-derived antioxidants." This mechanism regulates the amount of intracellular ROS. "We found that KEAP1 can change its function at high amounts of ROS and turns into a cell death mediator", continues Pichlmair. "We were able to identify molecules that are important for this signaling pathway." When components of this signaling pathway were removed experimentally, cells survived high levels of ROS. Since this is a new, previously unknown signaling pathway, the scientists call it "oxeiptosis" – death caused by oxygen radicals.
Oxeiptosis in viral infections
Pichlmair and colleagues were able to show that oxeiptosis is also activated during viral infections. When components of the oxeiptosis signaling pathway were removed, cells survived better after virus challenge. "Programmed cell death in complex organisms has evolved to protect the organism as a whole at the expense of individual cells," says Pichlmair. The importance of this cell death mechanism is emphasized by the ability of many evolutionarily distant viruses that can actively modulate this signaling pathway.
Infection of mice with the flu virus 'influenza' leads to inflammation in the lungs. If an essential part of the oxeiptosis pathway was absent in these animals, inflammatory processes were much more aggressive. Oxeiptosis therefore leads to an anti-inflammatory type of cell death. If cells are unable to activate this type of cell death due to pathological changes in critical components, an inflammatory cell death program will take over and cause serious tissue damage.
Oxeiptosis probably plays a role in many pathological situations. For example, it has already been described that essential components of the oxeiptosis pathway are mutated in certain cancers. By identifying this signaling pathway, the scientists hope to find new treatments against infectious diseases and cancer.
Holze C, Michaudel C, Mackowiak C, Haas DA, Benda C, Hubel P, Pennemann FL, Schnepf D, Wettmarshausen J, Braun M, Leung DW, Amarasinghe GK, Perocchi F, Staeheli P, Ryffel B, and Pichlmair A.: Oxeiptosis, an ROS-induced caspase-independent apoptosis-like cell-death pathway'. Nature Immunology, December 2017
Dr. Andreas Pichlmair
Group Leader +49 89 8578-2220 apichl@... MPI für Biochemie, Am Klopferspitz 18, 82152 Martinsried
Viral Immunopathology
Research Group "Innate Immunity"(Andreas Pichlmair)
Other Interesting Articles
Zika virus proteins inhibit brain development
In healthy individuals, the Zika virus causes flu-like symptoms. If a pregnant woman becomes infected, the unborn child can suffer from severe brain abnormalities as a result of mechanisms that have not yet been explained. A study by the Max Planck Institute of Biochemistry (MPIB) and the Technical University of Munich (TUM) shows that Zika virus…
'Bodyguard' Protein Helps Protect Young RNAs
RNA molecules perform key functions in the cell. They transmit genetic information as blueprints for proteins and fulfil other essential tasks. For this purpose, they undergo a multi-step process during which they must be protected from premature degradation. Scientists from the Max Planck Institute (MPI) of Biochemistry in Martinsried have now…
EU-Funding for a Net to trap Viruses
Award Grant Pichlmair
The ERA-NET programs of the European Commission aim to better coordinate pan-European research funding and to bundle the continent's scientific expertise. A project which is overseen by Andreas Pichlmair at the Max Planck Institute (MPI) of Biochemistry in Martinsried near Munich (Germany) now receives one of the coveted grants supporting the researchers with more than two million Euros. The multinational team aims to identify evolutionary conserved defense mechanisms against viruses.
About 4.5 Million Euros Funding for Group Leaders at the MPIB
Award Grant Lorentzen Pichlmair Schnorrer
The European Research Council (ERC) encourages excellent basic research in Europe in order to promote visionary projects and open up new interdisciplinary science areas. Three young group leaders of the Max Planck Institute of Biochemistry (MPIB) in Martinsried near Munich succeeded in obtaining one of the coveted "ERC Starting Grants". Spread over…
Weak Points in the Human Immune System - Max Planck Researchers Investigate the Attack Strategies of Viruses
For viruses to spread, they must enter host cells to replicate, assemble and propagate. Scientists of the Max Planck Institute (MPI) of Biochemistry in Martinsried near Munich and the Research Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences in Vienna have for the first time performed a comprehensive survey of the antiviral…


On a day that we are reminded that nothing in life is free, I would like to present our readers six tax day freebies in the form of real estate graphs that clearly demonstrate current trends in the Tallahassee real estate market recovery.
We will take a close look at property types and distressed home sales, which should provide homeowners with an understanding of what is happening to the value of their homes.
Our first tax day freebie contains information that you need to know if you are getting ready to sell a home, buy a home, or invest in the Tallahassee real estate market in any way.
This graph clearly shows that distressed home sales are on the rise, as roughly 1 in every 3 transactions is a short sale, foreclosure, or bank owned property. This is tough for existing homeowners, because that means a full third of their competition just wants to get rid of the property, and the sales price is a secondary consideration.
Those distressed properties are keeping buyers active, as the first quarter of 2014 out-performed all years prior going back to 2008.
The major question that looms for the Tallahassee real estate market is how many more distressed properties need to clear the market? We have to wonder whether a flood of properties is waiting around the next corner, or perhaps will their be price-shock for buyers coming soon if we conclude the cleansing of the market.
Condominium Values On The Mend?
2014 has delivered lower values for single family detached homes and townhouses, but condominium values have shot upwards.
This is less a move in market values, and more a picture of what happens in a low liquidity market (condo sales in Tallahassee) when product mixes change. The fact is we are seeing some of the downtown market wake up, and with so few condominiums sold, their impact on "average" condo values is very clearly fogging our results.
Single family detached home prices and values are coming down thus far in 2014. So too are townhouses.
I suspect this is nothing more than a normal blip in an upwardly moving market. Values and prices soared in 2013, it is only logical that we would see some regression as distressed home sales "confused" buyers. When we see distressed sales begin to decline, you can expert this short term reprieve to reverse.
The difference between arms length home values and distressed home values was at its widest margin last year, and buyers are being pulled to values in short sales and foreclosures.
This has caused competition for distressed properties and we are seeing values rise, while it has reduced the competition among arms length sellers, thus values are under pressure.
Our final tax day freebie shows that the majority of distressed properties that are selling are below the median home price in Tallahassee.
This means that when we compare the average prices and values of distressed properties with those of arms length properties, we are not really comparing apples to apples. Investment properties still dominate the distressed sales, so we have to take these relative images with a grain of salt and ensure that we do a detailed evaluation for every specific situation for which you find yourself. Never apply market averages directly to your specific scenario, adjustments need to be made.
OK, I admit, free pictures of the housing market weren't nearly as good as your federal tax liability was bad, but ... we tried :).
If you want to know how to use the information from your 6 tax day freebies to make a move in the Tallahassee real estate market, just drop me a note and we will schedule a time to review your specific needs and wants, and then get you moving!


amazon› Search› 6 inch steel pipe price Amazon: 6 inch steel pipe price. From The Community. Try Prime All ... Heavy duty, rigid high-carbon steel blade will not bend. Hardened ... Schluter Kerdi 32-Inch X 60-Inch Off-Center Shower Kit with Stainless Steel Drain. by Schluter. $464.97 $ 464 97. FREE Shipping on eligible orders.
There are 17,358 6 inch steel pipe suppliers, mainly located in Asia. The top supplying countries are China (Mainland), India, and Malaysia, which supply 99%, 1%, and 1% of 6 inch steel pipe respectively. inch steel pipe products are most popular in Southeast Asia, Mid East, and South America.
Cover or close the end of a carbon steel pipe with these caps. Carbon steel is stronger than stainless steel, is very resistant to wear, and can withstand high pressure, but is also susceptible to corrosion.
ebay› Search› 6 inch stainless steel pipe Find great deals on eBay for 6 inch stainless steel pipe. Shop with confidence.
3 inch carbon steel pipe elbow - natural-elements-online. 3 Inch 90 Degree Carbon Steel Elbow, Wholesale Various High Quality 3 Inch 90 Degree Carbon Steel Elbow Products from Global 3 Inch 90 Degree Carbon Steel Elbow Suppliers and 3 Inch 90 Degree Carbon Steel Elbow Factory,Importer,Exporter at Alibaba.
And whether 3 inch steel pipe is structure pipe, fluid pipe, or oil pipe. There are 23,283 3 inch steel pipe suppliers, mainly located in Asia. The top supplying countries are China (Mainland), Taiwan, and India, which supply 99%, 1%, and 1% of 3 inch steel pipe respectively.
20 inch carbon steel seamless pipe price per meter. Product Description. Product Image . Commodity 20 inch carbon steel seamless pipe price per meter: Brand. Wugang mill, Shougang mill, Angang mill, Jigang mill, Baosteel etc. Certification. ISO, SGS, BV, CE or as required. Thickness. 1mm-56mm.
28 inch 20 inch carbon steel pipe diameter 1500mm. Product Description. Product Image . Commodity 28 inch 20 inch carbon steel pipe diameter 1500mm: Brand. Wugang mill, Shougang mill, Angang mill, Jigang mill, Baosteel etc. Certification. ISO, SGS, BV, CE or as required. Thickness. 1mm-56mm.
Give us a call today to get all the information, +91-9819591024, If you're looking to buy or sell 10 Inch ANSI B36.10 Carbon Steel Pipe, we can help., call to our Distributor in India or mail us to [email protected] for instant free quote of 10 Inch ANSI B36.10 Carbon Steel Pipe.


Samsung has finally launched the mini version of S5 – Samsung Galaxy S5 mini Duos. The new S5 mini SM-G800 is priced at RS 26499 in India. The Galaxy S5 mini Duos SM-G800 has 4.5 inch Super AMOLED display with 1280 x720 pixels resolution and draws the strength from 1.4GHz quad core Snapdragon 400 MSM8228 processor. It runs on Android 4.4 Kit-Kat operating system. It supports DUAL SIM and houses 2100 mAh battery. It would compete with Samsung Galaxy S4, Gionee Elife E7, Xiaomi Mi3 and Micromax Canvas Knight A350.
The Galaxy S5 mini packs with 8-megapixel rear camera with LED flash and a 2.1MP front shooter. It has IP67 rating for Dust and water Resistance. It is 9.1mm thick and weighs 120 grams. There is 1.5GB RAM under the hood. It also features infrared LED for smartTV remote, Heart rate sensor and S health.
It has 16GB of internal storage and further you can expand it up to 64GB via micro SD card. It is powered by 2100mAh battery. It offers 3G HSPA+, dual Band Wi-Fi 802.11 a/b/g/n HT40, Bluetooth v4.0 Le,GPS and NFC. The S5 mini is also known as SM-G800H in the USA and SM-G800F for Europe.
The Samsung Galaxy S5 mini Duos will be available in Black, White, Blue and Gold colors. You can buy it online exclusively from Flipkart.


A broad array of recreational opportunities, raceways, waterfronts, not to mention historical sites and farmland sites, and sounds make Dinwiddie one of Virginia's most attractive and popular playgrounds! Dinwiddie has something for everyone. History buffs, extreme sports enthusiasts, nature and wildlife fans, and foodies will all find parts of Dinwiddie that will meet their appeal. View some of the Dinwiddie County Tourism exciting assets.


This may mean that the Xbox console needs a software update.
When the files have been burned to disc, remove the disc from your computer and insert it in the disc drive on your Xbox 360 console.
If you still experience the problem, click the "Contact us" link at the bottom of this page to contact Xbox Support.
Would you like to contact Support regarding the "Error D0000033 occurs when you try to connect to Xbox Live" issue you were reading about or a different issue?


Necessary Step or Environmental Disaster?
Opinion & Analysis: Should Florida allow offshore drilling?
An energy bill amendment that would permit offshore drilling in Florida is expected to reach the Senate this fall, but how might it impact Florida tourism and the environment?
Earlier this month, Reuters reported that an energy bill amendment adopted by the U.S. Senate Energy and Natural Resources Committee would permit offshore drilling up to 45 miles off the Gulf Coast of Florida. Currently, drilling for oil and gas is banned within 125 miles of the coast to protect the environment and the tourism industry.
The amendment also would allow drilling in the Destin Dome area, about 25 miles south of Pensacola, which is estimated to offer "at least 2 trillion cubic feet of natural gas," the equivalent of 15 years' worth of heat for two million homes, Reuters reported.
According to the South Florida Sun-Sentinel, the amendment has oceanographers very concerned. If a leak should occur, Florida's rapid "loop current" could carry an oil spill into the Florida Keys, the Gulf Stream, the Florida Straits and eventually north to southeastern Florida beaches. The Sun-Sentinel reports that "even a small oil spill ... would threaten the ecosystem of the Keys and potentially pollute the eastern shores."
The energy bill is advancing in the Senate, The Huffington Post reported, but Democrats and Republicans have both "expressed concerns" and are hoping to "make major changes when it reaches the Senate floor, probably in the fall."
NaturalGas.org outlines the history of drilling for natural gas offshore, and explains in words and photos how the process works. Although drilling on land allows for a platform-like surface from which to drill, water makes things less stable, so a platform must be constructed.
"This artificial platform can take many forms, depending on the characteristics of the well to be drilled, including how far underwater the drilling target is," according to NaturalGas.org. In some cases, a platform or "fixed platform rig" can be attached to the ocean floor. There are also "moveable rigs," which are often less expensive and used "for exploratory purposes."
Offshore drilling was initiated "as early as 1869" by T.F. Rowland, whose rig design resembles offshore rigs used today. It wasn't until 1947 that an offshore well was built in the Gulf of Mexico.
Considering a vacation to sunny Florida? See findingDulcinea's Florida Travel Web Guide for advice on flights and hotels, tips for where to go and what to do, and ideas on how to get around the state.
Citing financial and environmental reasons, the Florida Coastal and Ocean Coalition has urged congressional delegates to renew Florida's moratorium on offshore drilling when they vote in September.
Environmental risks are very real, according to the Coalition, which cites documentation from the U.S. Minerals Management Services that Hurricanes Katrina and Rita caused more than "743,000 gallons of petroleum products to spill offshore and 457 pipelines to break."
Furthermore, "the complex infrastructure needed to explore, produce and bring petroleum ashore is highly vulnerable, and threatens coastal resources our Nation has invested billions to protect." Florida sees $65 billion annually from tourism, and nearly one million jobs are supported by the tourism sector.
Despite claims that offshore drilling would result in lower gas prices, such results would not happen any time soon, according to NPR. Although "there may be 18 billion barrels of oil in coastal waters," drilling there would not significantly impact "production or prices until 2030," NPR quoted the Department of Energy as saying. Oil industry executives concur that "drilling won't ease the oil pinch," reported NPR.
In order to stop drilling near the Florida coast in 2002, former President George W. Bush bought back seven "federal leases from oil companies" in the Destin Dome area for more than $100 million. In addition to improving Gov. Jeb Bush's reputation in Florida, the decision bolstered the president's environmental record. "But it was a costly way to prolong the inevitable: more offshore drilling," wrote David Abraham in the Foreign Policy Association Energy blog.
The current offshore drilling amendment is an attempt by Sen. Byron Dorgan, D-N.D., and other democrats "to get more Republican senators on board with a larger climate bill," wrote Abraham.
But could there be a way for environmentalists, and tourism and government officials, to come to an agreement on the issue?
A 2008 NPR article suggested that Florida tourism officials were "rethinking" their view of offshore drilling, led by Gov. Charlie Crist, who cited rising gas prices as a reason to drill off the Florida coast. "We're a tourist state," Crist told NPR. "We have to protect the beauty of Florida, but we also need to have people have the opportunity to drive here and be able to afford to do that, too."
Although tourism officials have consistently been opposed to offshore drilling, improvements in drilling methods had caused some to re-evaluate their stance. Robert Skrob, the executive director of the Florida Association of Convention and Visitors Bureaus, told NPR, "We hear that there's new technology. We hear there [are] new processes. We hear everything is a lot safer."
An editorial in The Ledger (Lakeland, Fla.) in favor of offshore drilling said the practice could be extremely financially beneficial for the state "when accompanied by balanced and reasonable regulations and oversight."
The editorial cited the fact that Louisiana's state education system is funded mostly by "energy production royalties" as one reason for Florida to drill offshore. In addition, offshore drilling would create manufacturing jobs in Florida, the author contended.


text:
Latest News About the Tools We Use	by Michael Murie
Switching from a DSLR to the Canon C100: Interview with Ben Pender-Cudlip
by Michael Murie
in Cinematographers, Cinematography, Columns, Filmmaking, Interviews
Cameras, Canon, Canon C100, Shooting
Ben Pender-Cudlip is a Boston based filmmaker who specializes in nonfiction work. His short film Sanjiban, which chronicles the passing of filmmaker Sanjiban Sellew, premiered at Hot Docs last year.
Ben recently switched from shooting on a DSLR to the Canon C100. In part one of this interview he talks about his experience switching to the C100, and in part two he talks about the first major project shot with the camera: documenting an ice-climbing expedition.
Filmmaker: What were you using prior to getting the C100?
Pender-Cudlip: Before the C100 I was using a Canon 60D, which is sort of your standard DSLR crop-sensor camera. I kitted it out with all the stuff to make it work for video. Most of what I do is observational documentary, so I've got the camera on my shoulder and I'm shooting for hours at a time trying to be unobtrusive. Dual-system sound isn't really a good option for that type of thing, so I shot with the 60D using an on-camera mixer called the MixPre-D by Sound Devices and fed two XLR signals into it. I had a shoulder rig using a wireless lavaliere and a shotgun.
Filmmaker: Were you considering any other cameras or did the C100 seem the only option?
Pender-Cudlip: I've been really sick of all the DSLR hassles for quite a while. There's just so much friction to using them in a run-and-gun situation. I'd been looking for another solution, and the Canon C300 just wasn't going to be it because it's so expensive.
I looked at a couple of Sony's that are big chip cameras, but I really didn't like the lens solutions for any of them.
When the C100 came out it was like the camera was made for me — as though they sat down and said, "What do you want?" It was everything I wanted; it uses the same glass that I use, my SD cards work in it, all of my gear works on it great. It was a drop-in replacement to my existing camera.
Filmmaker: What's it been like using it?
Pender-Cudlip: I was pretty astounded by how well it performed in low light — you can crank the ISO through the roof and it still looks good, and when it gets noisy and grainy the grain has this organic feel to it. It's kind of like film grain as opposed to the multi-colored fixed-pattern noise I'm used to on DSLRs where you can really see these nasty gross artifacts. That was surprising, and I was really delighted about that, by how far I could push it in low light.
I was expecting the ergonomics to be a bit weird. I was expecting to have to use it on some sort of rig, but actually just using it as is — the body with a shoulder strap — has been fine, so that was a really pleasant surprise too.
Filmmaker: Anything you don't like about the camera?
Pender-Cudlip: The built-in EVF — the viewfinder that you put your eye up against — is a little bit worse than I had expected. It's tiny, it's like squinting at a postage stamp. And you need to put some sort of padding on it because when you put your face up against it the cover doesn't even seal out the light. Once I taped a little microfiber eye-cushion from Blue Star to the EVF, my life got a lot better.
Filmmaker: What lenses are you using most frequently?
Pender-Cudlip: My standard run-around lens is a Tamron 17-50mm f2.8 IS, mostly because I've been using that forever and pulling focus on it is like second nature for me now. I've got a lot of muscle memory built in to that lens. I am also using the Canon 70-200 IS II that's f/2.8.
Filmmaker: How do you use it hand held?
Pender-Cudlip: It's good to use hand held, especially if I sling the camera down around my belly with the neck strap. It's pretty damn stable. You can't shoot for an extended period of time with it up to your face because the lens is so damn heavy, so I'll do a bunch of hand-held shots like that.
I have a little holster from Lowepro that sits on my waist. When you unzip the holster a sort of accordion opens and there are two pockets. I can take one lens off the camera, put it in one of the pockets, then take the lens out of the other pocket and put it on the camera, and then with one hand zip up the lens case. So I can switch lenses on the fly, in and out in 10-15 seconds, without having to set anything down, which is really nice.
Filmmaker: Do you have to switch off the C100 when you switch lenses?
Pender-Cudlip: You know that's a really good question. I don't know! I'm used to not turning off my camera when I switch lenses on the 60D, and I know that on the C300 there's this capacitor that blows if you switch lenses while it's on. And the C500 has this lens exchange button where it powers down the camera real quick.
When I remember to, I try and turn the camera off. I've seen it both ways online; I haven't messed it up yet so I'll see. I'd like to know the official line from Canon because the camera takes a while to turn off and turn on. It takes like four or five seconds to turn off and then a good 10 or 15 to turn on, so that's a pain in the ass [For a warning about changing lenses, see note below.]
Filmmaker: Have you bought any new accessories with this camera or are you mostly using what you already had?
Pender-Cudlip: Being documentary, I want to have as little as possible hanging off the camera. I don't use an external monitor; the peaking on the unit is pretty good, and I'm pretty good at focusing from all my time on the DSLR, so that's not really a problem.
I don't use external recorders because that's a pain in the ass. For most of what I do, which goes to the web, I don't really care if it's 4:2:0 at 24m/bits, it still looks good.
Filmmaker: What about using it on a rig?
Pender-Cudlip: I used it for half a day on a Cowboy Studio shoulder rig, but it's not really in the right position, and I've been pretty happy working with it rigless. If I'm doing an extended interview what I'll do is just jam it on a mono-pod, but other than that it's been pretty agile and surprisingly stable.
Filmmaker: Has using it changed in any way how you're working or shooting?
Pender-Cudlip: It's easier to have it on me, hanging off my shoulder strap, and just pull it up and knock off a few shots. With my old rig, it was like this monstrosity with all these things attached and you couldn't set it down. It was really hard to hold. There's a lot less friction using this in the real world; it's a lot easier to grab and shoot.
Filmmaker: Anything you'd change about the camera?
Pender-Cudlip: Personally I'm considering getting the Canon 24-105 lens just because this camera is so good in low light, I don't think I'm going to miss that stop between 2.8 and 4.0. But that's not really something about the camera.
Honestly there's not much. It would be nicer if it recorded 4:2:2 and I would love 60p. I don't do much over-cranking but that would be kind of nice to have.
EOS C100 Instruction Manual
[NOTE: the EOS C100 Instruction Manual contains instructions for "Attaching an EF Lens" that starts with "1. Set the POWER switch to OFF."
However, while the manual contains several IMPORTANT warnings advising that you turn off the camcorder before connecting or disconnecting the compact power adapter, and to avoid direct sunlight while changing lenses, there is no such IMPORTANT warning about powering off while changing lenses.
Another C100 owner – who also owns a C300 – has adamantly told me that you must turn off the camera while switching lenses.]
Photo: Lauren Schaad
"Black Life Has Always Been Better Than Black Cinema": Documentary Makers Speak at Full Frame's "Black Frame: New Voices of Documentary" A&E IndieFilms Speakeasy Video
A Process of Subtraction: Sean Durkin on His Disquieting Family Drama, The Nest Video
Silent Running, Year of the Dragon and Rolling Thunder Revue: Jim Hemphill's Home Video Recommendations Video
2013 Oscar Nominees Announced By Billy Brennan on Jan 10, 2013
Sun Don't Shine Acquired by Factory 25 for World Distribution By Billy Brennan on Jan 16, 2013
The New Digital Storytelling Series: Hugues Sweeney By MIT Open Documentary Lab on Mar 21, 2013
Five Questions with 56 Up Director Michael Apted By David Licata on Jan 3, 2013


Best Low Price Air Max Zero QS Day White Yellow Running Shoes are for clearance sale. Welcome to purchase nice air max price and cheap all grey nike air max sale. You will be satisfied with nice buy nike air max online. Cheap cheap air max 2016 are quite loved by all age of people. Our online store provides all sizes and styles of new cheap jordan shoes. More order, more discounts. Best nike air black and white is the instant hit for the footwear field. Look for cheap nike air max 90 2017 at our shoes shop and get more information.